Evolution of SARS-CoV-2 variants: implications on immune escape, vaccination, therapeutic and diagnostic strategies
NZ Zabidi, HL Liew, IA Farouk, A Puniyamurti, AJW Yip… - Viruses, 2023 - mdpi.com
The COVID-19 pandemic caused by SARS-CoV-2 is associated with a lower fatality rate
than its SARS and MERS counterparts. However, the rapid evolution of SARS-CoV-2 has …
than its SARS and MERS counterparts. However, the rapid evolution of SARS-CoV-2 has …
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA. 2 and BA. 5 subvariant predominance: A systematic literature …
M Drysdale, M Berktas, DC Gibbons, C Rolland… - Infection, 2024 - Springer
Purpose To evaluate clinical outcomes associated with sotrovimab use during Omicron BA.
2 and BA. 5 predominance. Methods Electronic databases were searched for observational …
2 and BA. 5 predominance. Methods Electronic databases were searched for observational …
COVID-19: An Update on the Latest Therapeutic Agents
The COVID-19 pandemic has plagued the world for over three years since discovering the
causative virus, SARS-CoV-2, in China. The rampant spread of the virus led to the loss of …
causative virus, SARS-CoV-2, in China. The rampant spread of the virus led to the loss of …
[HTML][HTML] Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild …
J Calderón-Parra, A Gutiérrez-Villanueva… - International Journal of …, 2024 - Elsevier
Introduction Antivirals and monoclonal antibodies lower the risk of progression in
immunocompromised patients. However, combination therapy with both types of agents has …
immunocompromised patients. However, combination therapy with both types of agents has …
Use of monoclonal antibodies in immunocompromised patients hospitalized with severe COVID-19: a retrospective multicenter cohort
J Calderón-Parra, P Guisado-Vasco… - Journal of clinical …, 2023 - mdpi.com
Objective: We aim to describe the safety and efficacy of sotrovimab in severe cases of
COVID-19 in immunocompromised hosts. Methods: We used a retrospective multicenter …
COVID-19 in immunocompromised hosts. Methods: We used a retrospective multicenter …
[HTML][HTML] COVID-19 treatment strategies with drugs centrally procured by the German Federal Ministry of Health in a representative tertiary care hospital: a temporal …
K Marx, S Kalbitz, N Kellner, M Fedders… - GMS Infectious …, 2023 - ncbi.nlm.nih.gov
Methods: A descriptive analysis of hospitalization and treatment of COVID-19 patients with
drugs centrally procured by the BMG at St. Georg Hospital, Leipzig, Germany, for the period …
drugs centrally procured by the BMG at St. Georg Hospital, Leipzig, Germany, for the period …
Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID‐19: A systematic review and meta‐analysis
Abstract Background and Aim This systematic review and meta‐analysis aimed to compare
the effectiveness and safety of molnupiravir and sotrovimab in the treatment of patients with …
the effectiveness and safety of molnupiravir and sotrovimab in the treatment of patients with …
Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis
Background This study aims to compare the effectiveness and safety of nirmatrelvir/ritonavir
(Paxlovid) and sotrovimab for coronavirus disease 2019 (COVID-19). Methods A search was …
(Paxlovid) and sotrovimab for coronavirus disease 2019 (COVID-19). Methods A search was …
[HTML][HTML] Efficacy of bamlanivimab compared to standard care in treatment of the patients with COVID-19: A Systematic Review and Meta-Analysis
S Khorramnia, M Jalili, M Salajegheh… - Studies in Medical …, 2023 - umj.umsu.ac.ir
Background & Aims: Bamlanivimab is a monoclonal antibody for the treatment of mild to
moderate cases of Coronavirus disease 2019 (COVID-19). The aim of the current meta …
moderate cases of Coronavirus disease 2019 (COVID-19). The aim of the current meta …
Efficacy and safety of regdanvimab in patients with mild to moderate COVID‐19: A rapid review and meta‐analysis
Aims This study aimed to evaluate the efficacy and safety of regdanvimab, an anti‐SARS‐
COV‐2 monoclonal antibody approved by the European Medicines Agency in November …
COV‐2 monoclonal antibody approved by the European Medicines Agency in November …